Sebastian A Wohlfeil
Overview
Explore the profile of Sebastian A Wohlfeil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoffmann J, Schuler J, Dietsch B, Kurschner-Zacharias S, Sticht C, Trogisch F, et al.
Cancer Metab
. 2025 Jan;
13(1):5.
PMID: 39875968
Background: In malignant melanoma, liver metastases significantly reduce survival, even despite highly effective new therapies. Given the increase in metabolic liver diseases such as metabolic dysfunction-associated steatotic liver disease (MASLD)...
2.
Haggenmuller S, Wies C, Abels J, Winterstein J, Heinlein L, Nogueira Garcia C, et al.
Nat Commun
. 2025 Jan;
16(1):789.
PMID: 39824857
Accurate melanoma diagnosis is crucial for patient outcomes and reliability of AI diagnostic tools. We assess interrater variability among eight expert pathologists reviewing histopathological images and clinical metadata of 792...
3.
Kott J, Zell T, Zimmermann N, Runger A, Smit D, Abeck F, et al.
Eur J Cancer
. 2024 Dec;
214():115159.
PMID: 39642845
Background: Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing anti-tumor treatment is through...
4.
Utikal J, Wohlfeil S, Bauer-Auch C, Vogel T, Koy A, Morakis P
J Eur Acad Dermatol Venereol
. 2024 Nov;
PMID: 39600188
No abstract available.
5.
Ozbay Kurt F, Cicortas B, Balzasch B, de la Torre C, Ast V, Tavukcuoglu E, et al.
J Immunother Cancer
. 2024 Sep;
12(9).
PMID: 39266214
Background: Immunotherapies for malignant melanoma are challenged by the resistance developed in a significant proportion of patients. Myeloid-derived suppressor cells (MDSC), with their ability to inhibit antitumor T-cell responses, are...
6.
Wohlfeil S, Kranzmann L, Weiss C, von Wasielewski I, Klespe K, Kahler K, et al.
Int J Cancer
. 2024 Jul;
155(10):1808-1823.
PMID: 38975881
This study investigated whether adjuvant treatments in stage III cutaneous melanoma (CM) influenced patterns of recurrence. Patients with primary (n = 1033) or relapsed CM (n = 350) who received...
7.
Wohlfeil S, Olsavszky A, Irkens A, Hafele V, Dietsch B, Straub N, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38275881
Background: This study analyzed the role of Stabilin-1 on hepatic melanoma metastasis in preclinical mouse models. Methods: In mice (Stab1 KO), liver colonization of B16F10 and Wt31 melanoma was investigated....
8.
Wohlfeil S, Geraud C
J Dtsch Dermatol Ges
. 2023 Oct;
22(1):18-21.
PMID: 37884458
The treatment of metastatic cutaneous melanoma was fundamentally improved by the discovery and introduction of immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, and targeted therapy with BRAF and...
9.
Dietsch B, Weller C, Sticht C, de la Torre C, Kramer M, Goerdt S, et al.
BMC Cancer
. 2023 May;
23(1):436.
PMID: 37179302
Background: Liver metastasis is a poor prognostic factor for treatment of advanced cutaneous melanoma with either immunotherapy or targeted therapies. In this study we focused on NRAS mutated melanoma, a...
10.
Jauch A, Wohlfeil S, Weller C, Dietsch B, Hafele V, Stojanovic A, et al.
Cancer Cell Int
. 2022 Dec;
22(1):398.
PMID: 36496412
Background: Hyaluronan receptor LYVE-1 is expressed by liver sinusoidal endothelial cells (LSEC), lymphatic endothelial cells and specialized macrophages. Besides binding to hyaluronan, LYVE-1 can mediate adhesion of leukocytes and cancer...